Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy

References

• Jaffe E S, Harris N L, Stein H, Vardiman J. World Health Organisation Classification of Tumours, Vol 3: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon, France 2001
   Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Barth T F, Leithauser F, Joos S, Bentz M, Moller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand?. Lancet Oncol 2002; 3: 229–234
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15: 1646–1653
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Boveri E, Morra E, Brusamolino E, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11: 2306–2313
   PubMed Web of Science ®Google Scholar
• Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp M A, Kaplan W D, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993; 11: 1336–1343
   PubMed Web of Science ®Google Scholar
• Savage K J, Monti S, Kutok J L, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Plonquet A, Alonso M A, Boulland M L, Marquet J, Divine M, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002; 15: 1172–1180
   PubMed Web of Science ®Google Scholar
• Bentz M, Barth T F, Bruderlein S, Bock D, Schwerer M J, Baudis M, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001; 30: 393–401
   PubMed Web of Science ®Google Scholar
• Joos S, Otano-Joos M I, Ziegler S, Bruderlein S, du Manoir S, Bentz M, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996; 87: 1571–1578
   PubMed Web of Science ®Google Scholar
• Melzner I, Bucur A J, Bruderlein S, Dorsch K, Hasel C, Barth T F, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005; 105: 2535–2542
   PubMed Web of Science ®Google Scholar
• Hamlin P A, Portlock C S, Straus D J, Noy A, Singer A, Horwitz S M, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130: 691–699
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372–376
   PubMed Web of Science ®Google Scholar
• Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, et al. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant 2002; 29: 473–477
   PubMed Web of Science ®Google Scholar
• Savage K J, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne R D, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17: 123–130
   PubMed Web of Science ®Google Scholar
• Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d'Agay M F, Baumelou E, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol 1996; 20: 877–888
   PubMed Web of Science ®Google Scholar
• van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19: 1855–1864
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Martelli M, Bertini M, Gianni A M, Devizzi L, Federico M, et al. International Extranodal Lymphoma Study Group (IELSG). Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258–1264
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, Molina T J, Brice P, Coiffier B, et al. Groupe d'Etude des Lymphomes de l'Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197–1205
   PubMed Web of Science ®Google Scholar
• Shipp M, Harrington D, Anderson J R, Armitage J O, Bonadonna G, Brittinger G, et al. The International non-Hodgkin's Lymphoma Prognostic Factor Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Tilly H, Mounier N, Lederlin P, Brière J, Dupriez B, Sebban C, et al. Randomized comparison of ACVBP ad m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH 87–1 study. J ClinOncol 2000; 18: 1309–1315
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284–4289
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH-87 protocol. A Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030
   PubMed Web of Science ®Google Scholar
• Hill D A, Gilbert E, Dores G M, Gospodarowicz M, van Leeuwen F E, Holowaty E, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005; 106: 3358–3365
   PubMed Web of Science ®Google Scholar
• Travis L B, Hill D, Dores G M, Gospodarowicz M, van Leeuwen F E, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 1428–1437
   PubMed Web of Science ®Google Scholar